Jay Backstrom, Scholar Rock CEO
October 7, 2024 11:47 AM EDT
R&D

Schol­ar Rock claims suc­cess in Phase 3 spinal mus­cu­lar at­ro­phy study, stock soars

Lei Lei Wu

News Reporter

Schol­ar Rock an­nounced its ex­per­i­men­tal add-on treat­ment for spinal mus­cu­lar at­ro­phy sig­nif­i­cant­ly im­proved mo­tor func­tion com­pared to place­bo at one year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times